Type: Oral
Session: 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Treatment of BCR:ABL+ and T Cell Diseases
Hematology Disease Topics & Pathways:
Research, Combination therapy, Translational Research, Treatment Considerations, Adverse Events, Measurable Residual Disease
Methods. Between September 2021 and July 2024, 200 newly diagnosed adult Ph+ ALL patients were enrolled. One hundred thirty three patients were randomized to the experimental arm that contemplated a steroid pre-phase followed by a 70-day induction with ponatinib at 45 mg or 30 mg according to age (less or more than 65 years) followed by at least 2 cycles (maximum 5) of blinatumomab. Median age was 57 years (20-87), 27% of patients being >65 years; 52% were female, the white blood count was 11x109/l (1-244); the p190 protein was detected in 70% of cases and 30% carried the p210 or 190/p210 protein.
Results. By the end of the induction, 110 patients (95%) achieved a CHR; 4 (3%) died in induction (pneumonia in 2, ileus paralyticus in 1 and death of unknown causes in 1) and 2 (1.5%) went off-study due to cardiac toxicity, while being in CHR. The remaining 17 cases are still receiving induction. A MRD response (complete molecular response plus positive non quantifiable) was recorded in 45% of cases.
By the end of the second cycle of blinatumomab, 93 of the 95 evaluable patients (98%) were in CHR, 1 withdraw consent due to non-compliance and 1 experienced a hematologic relapse. MRD response raised to 73%.
Overall, 52 grade >3 adverse events due to ponatinib were recorded, the most frequent being hepatic (20), hematologic (12) and pancreatic (8); cardiac toxicities were relatively rare, with only 5 events; finally, 5 infectious episodes (2 sepsis) and 2 cutaneous events were also reported.
The combination of ponatinib with blinatumomab led to 18 grade >3 adverse events: 8 were hematologic (5 in a single case), 4 were infections, 2 cytokine release syndromes and 2 neurologic related events were documented, as well as 2 gastrointestinal events.
Forty percent of patients required a dose reduction and/or a transient interruption: the most frequent toxicities were represented by grade 3 transaminitis in 10 patients and grade 2 in 6; an increase in pancreatic enzymes was observed in 6 cases (4 grade 3 and 2 grade 2); a cardiac toxicity was recorded in 6 patients, leading to a permanent discontinuation only in 2 cases. Other adverse events requiring a dose reduction were cutaneous rush, pharyngeal abscess, COVID-19 infection, and hematologic toxicity, documented in 1 case each. There was not a significant enrichment of toxicity leading to dose reduction/transient interruption in elderly.
So far, only 3 relapses (3%) have been recorded: 1 was BCR::ABL1-negative, suggesting the presence at diagnosis of a non Ph+ subclone, and 1 was recorded in a case who discontinued treatment for cardiovascular toxicity. Transplant allocation was based on an IKZF1plus profile at presentation and MRD persistence; so far, only 12% of patients have been allografted. At a median follow-up of 6.4 months (range 0.1-32.3), the estimated 18-month OS is 91.6%.
Conclusions. The intermediate analysis of the GIMEMA ALL2820 trial shows the feasibility and efficacy of a frontline chemo-free induction/consolidation approach with ponatinib and blinatumomab for Ph+ ALL adults of all ages. The combination was overall well tolerated, with very few treatment discontinuations, also in the elderly, suggesting that a ponatinib dose adjustment according to age may prevent severe toxicities. Lastly, with the biology-driven transplant allocation only 12% of patients have been transplanted so far.
Disclosures: Chiaretti: Abbvie: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees. Borlenghi: Amgen: Other: Travel Grant; Abbvie: Consultancy; BMS: Consultancy; Incyte: Other: Travel Grant. Bonifacio: BMS: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria. Fracchiolla: Abbvie: Speakers Bureau; Jazz: Speakers Bureau; Amgen: Speakers Bureau; Pfizer: Speakers Bureau. Zappasodi: pfizer: Consultancy, Honoraria; Abbvie: Honoraria; astellas: Honoraria; Amgen: Honoraria. Bocchia: Novartis: Honoraria, Other: travel grant; Incyte: Honoraria, Other: travel grant; Abbvie: Honoraria, Other: travel grants. Rambaldi: Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Jazz: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Kite-Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Omeros: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau.
See more of: Oral and Poster Abstracts